A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis [AD] who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase [JAK] inhibitor treatment (NCT06241118)

Aqua EFC17599